New Analysis from Global Industry Analysts Reveals Steady Growth for Immuno-Oncology, with the Market to Reach $143.9 Billion Worldwide by 2026
28 Jun 2022
VaccineCollaborate
SAN FRANCISCO, June 28, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Immuno-Oncology - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
FACTS AT A GLANCE
Preview
Source: PRNewswire
New Analysis from Global Industry Analysts Reveals Steady Growth for Immuno-Oncology, with the Market to Reach $143.9 Billion Worldwide by 2026
What's New for 2022?
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year
Edition: 9;
Released: January 2022
Executive Pool: 7883
Companies: 102 - Players covered include AbbVie, Inc.; Aduro BioTech, Inc.; Amgen, Inc.; AstraZeneca PLC; Bavarian Nordic A/S; Bristol-Myers Squibb Company; Celgene Corporation; Celldex Therapeutics, Inc.; Eli Lilly and Company; EMD Serono, Inc.; F. Hoffmann-La Roche AG; Galena Biopharma, Inc.; Gilead Sciences, Inc.; ImmunoCellular Therapeutics Ltd.; Incyte Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.; Prometheus Laboratories, Inc.; Sanofi SA and Others.
Coverage: All major geographies and key segments
Segments: Cancer Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Cancer Types); Therapy Type (Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Other Therapy Types)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report.
Preview Registry
ABSTRACT-
Global Immuno-Oncology Market to Reach $143.9 Billion by 2026
Amid the COVID-19 crisis, the global market for Immuno-Oncology estimated at US$63.9 Billion, is projected to reach a revised size of US$143.9 Billion by 2026, growing at a CAGR of 14.3% over the analysis period. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is projected to record a 14.2% CAGR and reach US$143.5 Billion by the end of the analysis period. After an thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immune System Modulators segment is readjusted to a revised 15% CAGR for the next 7-year period.
The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 13.8% CAGR
The Immuno-Oncology market in the U.S. is estimated at US$18.9 Billion, while China is forecast to reach a projected market size of US$28.4 Billion by the close of the analysis period trailing a CAGR of 13.8%. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.7% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.
Cancer Vaccines Segment to Record 15.6% CAGR
In the global Cancer Vaccines segment, USA, Canada, Japan, China and Europe will drive the 15.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion will reach a projected size of US$4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
More
MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.
Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android
About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.
CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: [email protected]
LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp
Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./
Follow Us on Twitter
https://twitter.com/marketbytes
[email protected]
SOURCE Global Industry Analysts, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.